Researched and Curated by Clinical and Scientific Experts.

Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.

Not all reports are available for public preview. For more information, please contact us.

Mobile Medical Applications for Substance Use Disorder

Focus of the Report: Substance abuse and drug addiction are conditions that are notoriously difficult to treat with long-term success, as 40% to 60% of patients with drug addiction relapse. Mobile medical applications (MMAs) may fill gaps that currently exist in conventional treatment programs by enabling patients to better manage their care and track their health and wellnes…

read more

IpsiHand Upper Extremity Rehabilitation System

The IpsiHand Upper Extremity Rehabilitation System is a brain-computer-interface/robotic arm exoskeleton system for use in chronic stroke patients (≥ 6 months post-stroke) aged ≥ 18 years undergoing stroke rehabilitation, to facilitate muscle re-education and for maintaining or increasing range of motion in the upper extremity.

read more

Organ Care System (OCS) Heart

The OCS Heart is a portable extracorporeal heart perfusion and monitoring system indicated for the resuscitation, preservation, and assessment of donor hearts in a near-physiologic, normothermic, and beating state intended for a potential transplant recipient.

read more

Breyanzi (Lisocabtagene Maraleucel) for Large B-Cell Lymphoma

Breyanzi (lisocabtagene maraleucel [liso-cel]) is an autologous chimeric antigen receptor (CAR) T-cell therapy, a novel type of immunotherapy in which a patient’s own immune cells are genetically re-programmed to target and attack cancer cells. It is indicated for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after 2 or more lines of …

read more